Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01679249 · ClinicalTrials.gov registry record
Blood Volume Analysis and Related Outcomes in Hemodialysis
A clinical trial of End-Stage Kidney Disease, sponsored by VA New York Harbor Healthcare System.
- Completed
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT01679249: Completed study of End-Stage Kidney Disease, sponsored by VA New York Harbor Healthcare System.
NCT01679249 is a study of End-Stage Kidney Disease that has completed, run by VA New York Harbor Healthcare System. The registered enrollment target is 10 participants, below the 465-participant average among 20 other End-Stage Kidney Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01679249, a study of End-Stage Kidney Disease, has completed, sponsored by VA New York Harbor Healthcare System.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
An understanding of fluid changes that occur during hemodialysis (HD) with ultrafiltration (UF) is essential for determining the efficacy of HD, as well as for reducing complications related to hypovolemia or, conversely, chronic volume overload.
Primary Outcome
To compare the results obtained by two different methods of assessing BV: direct measurement of BV using the Blood Volume Analyzer (BVA-100) vs. indirect measurement of relative changes in BV using the Crit-Line Monitor (CLM III). Blood volume is measured in liters and compared with "ideal blood volume" nomograms. Crit-Line Monitor measures relative change in blood volume as a percentage change and does not have absolute values.
Conditions Studied
Study Locations (1)
New York
- New York Harbor VA Healthcare System Hemodialysis Unit - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-05 |
What the finished NCT01679249 record still lists
NCT01679249 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 465-participant average among 20 other End-Stage Kidney Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with End-Stage Kidney Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01679249 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01679249 about?
NCT01679249 is a clinical study titled "Blood Volume Analysis and Related Outcomes in Hemodialysis". An understanding of fluid changes that occur during hemodialysis (HD) with ultrafiltration (UF) is essential for determining the efficacy of HD, as well as for reducing complications related to hypovolemia or, conversely, chronic volume overload.
What is the current status of trial NCT01679249?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2012-01. Estimated completion is 2012-05.
What conditions does trial NCT01679249 study?
This clinical trial studies the following conditions: End-Stage Kidney Disease.
Who is sponsoring clinical trial NCT01679249?
This trial is sponsored by VA New York Harbor Healthcare System, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01679249 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End-Stage Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01679249's enrollment target sits among peer trials
10 20th of 20 the lowest of 20 other End-Stage Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End-Stage Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Incremental Hemodialysis: The TwoPlus Trial
RECRUITING · NA
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
-
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
RECRUITING · Phase 3
-
Symptom Monitoring in Hemodialysis
RECRUITING · NA
-
Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants
RECRUITING · NA
-
Pain Reduction Using NEurostimulation Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia